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Background: Consecutive treatment of normal heart with a high dose of isoproterenol and adenosine (Iso/Ade
treatment), confers strong protection against ischaemia/reperfusion injury. In preparation for translation of this
cardioprotective strategy into clinical practice during heart surgery, we further optimised conditions for this
intervention using a clinically-relevant dose of Iso and determined its cardioprotective efficacy in hearts isolated
from a model of surgically-induced heart failure.
Methods: Isolated Langendorff-perfused rat hearts were treated sequentially with 5 nM Iso and 30 μM Ade
followed by different durations of washout prior to 30 min global ischaemia and 2 hrs reperfusion. Reperfusion
injury was assessed by measuring haemodynamic function, lactate dehydrogenase (LDH) release and infarct size.
Protein kinase C (PKC) activity and glycogen content were measured in hearts after the treatment. In a separate
group of hearts, Cyclosporine A (CsA), a mitochondria permeability transition pore (MPTP) inhibitor, was added
with Iso/Ade. Failing hearts extracted after 16 weeks of ligation of left coronary artery in 2 months old rats were
also subjected to Iso/Ade treatment followed by ischaemia/reperfusion.
Results: Recovery of the rate pressure product (RPP) in Iso/Ade-treated hearts was significantly higher than in
controls. Thus in Iso/Ade treated hearts with 5 nM Iso and no washout period, RPP recovery was 76.3 ± 6.9% of
initial value vs. 28.5 ± 5.2% in controls. This was associated with a 3 fold reduction in LDH release irrespective to
the duration of the washout period. Hearts with no washout of the drugs (Ade) had least infarct size, highest
PKC activity and also showed reduced glycogen content. Cardioprotection with CsA was not additive to the
effect of Iso/Ade treatment. Iso/Ade treatment conferred significant protection to failing hearts. Thus, RPP
recovery in failing hearts subjected to the treatment was 69.0 ± 16.3% while in Control hearts 19.7 ± 4.0%. LDH
release in these hearts was also 3 fold lower compared to Control.
Conclusions: Consecutive Iso/Ade treatment of normal heart can be effective at clinically-relevant doses and
this effect appears to be mediated by glycogen depletion and inhibition of MPTP. This intervention protects
clinically relevant failing heart model making it a promising candidate for clinical use.
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Reperfusion following a prolonged period of ischaemia in-
duces myocardial dysfunction and necrotic damage [1]. Is-
chaemia and reperfusion–elicited tissue injury contributes
to morbidity and mortality in a wide range of pathologies
and is a major challenge during organ transplantation and
cardiothoracic, vascular and general surgery [2].
We have previously described a cardioprotective protocol
termed temperature preconditioning (TP) [3] where a few
brief episodes of hypothermic perfusion (at 26°C) inter-
spersed with normothermic perfusion (at 37°C) signifi-
cantly improved heart resistance to the subsequent index
ischaemia. The cardioprotective effect of TP, which exceeds
the effect of ischaemic preconditioning, is associated with
activation of protein kinases A (PKA) and C (PKC) and
can be abolished by inhibitors of PKA and PKC (H-89 and
chelerythrine, respectively) [3,4]. Furthermore, a combin-
ation of TP with the PKA inhibitor H-89 (which has no
direct effect on PKC) reduced activation of PKC indicating
that in the mechanism of TP, PKC activation occurs
downstream to activation of PKA [4]. Importantly, TP
mediated by the consecutive activation of PKA and
PKC protects hearts during global normothermic is-
chaemia and during hypothermic ischaemia and cardi-
oplegia [5]. When the consecutive activation of PKA
and PKC was mimicked pharmacologically using the
PKA activator isoproterenol (Iso) and the PKC activator
adenosine (Ade), it resulted in a highly potent cardiopro-
tective effect [4]. This was achieved using a concentration
of Iso (200 nM) significantly higher than the concentra-
tion of isoproterenol in blood plasma used clinically
(0.02-0.2 μg/kg/min; equivalent to about 1.3-13 nM)
[6]. In contrast, the concentration of adenosine used in
our experiments (30 μM) is considerably lower than
that used for blood cardioplegia during cardiac surgery
(1–2 mM) [7,8]. Therefore it is important to test both
drugs at concentrations that are clinically relevant. Fur-
thermore, in our earlier work investigating this interven-
tion, we had not explored what duration of the washout
period prior to ischaemia produced the maximal cardio-
protective effect by triggering signalling mechanisms.
It is now recognized that opening of the mitochondria
permeability transition pore (MPTP) plays a key role in me-
diating the irreversible damage of the myocardium during
reperfusion [9] and that a range of interventions that inhibit
pore opening, either directly or indirectly, are cardioprotec-
tive [10-12]. This was confirmed for the cardioprotective ef-
fect of consecutive Iso/Ade treatment with Iso used at
relatively high concentration [4] but has not been investi-
gated at a clinically relevant concentration. This can be
achieved by establishing whether the cardioprotective effects
of Iso/Ade treatment are additive to those of cyclosporine A
(CsA) which is one of the most effective inhibitors of MPTP
[13] widely used in experiments on isolated hearts.The presence of co-morbid illness can render the myo-
cardium resistant to cardioprotection against infarction
by physical or pharmacological stimuli [14]. Thus an im-
portant and necessary step towards translation of this
cardioprotective strategy into clinical practice is to study
the efficacy of consecutive Iso/Ade treatment in diseased
hearts.
Here we study whether our treatment is effective at low,
clinically relevant concentrations of Iso and optimize the
protocol of the consecutive Iso/Ade treatment. We con-
firm the underlying mechanism to be inhibition of MPTP
opening and that the treatment is effective in a surgically-
induced model of heart failure.
Methods
Unless otherwise stated, all biochemicals were purchased
from Sigma and general chemicals from Fischer Scientific
or VWR-Jencons.
Experimental Procedures
Heart perfusion and analysis of haemodynamic function
All procedures conform to the Directive 2010/63/EU of the
European Parliament and the Guide for the Care and Use
of Laboratory Animals published by the US National Insti-
tutes of Health (NIH Publication No. 85–23, revised 1996).
Ethical approval was granted by the University of Bristol,
UK. Two months old male Wistar rats (250–260 g) were
killed by stunning and cervical dislocation. Hearts (~0.75 g)
were rapidly removed into ice-cold Krebs-Henseleit buffer
(KH) containing (mM): NaCl 118, NaHCO3 25, KCl 4.8,
KH2PO4 1.2, MgSO4 1.2, glucose 11 and CaCl2 1.2, gassed
with 95% O2-5% CO2 at 37 °C (pH 7.4) and perfused in
Langendorff mode. The aorta was rapidly cannulated and
the heart perfused at a rate of 8 ml · min−1 · g−1 heart weight
with in-line filter using KH. Monitoring of left ventricular
pressure was performed with a water-filled balloon inserted
into the left ventricle, set to give an initial left ventricular
end diastolic pressure (LVEDP) of 2.5–5 mmHg. All
hearts were allowed an equilibration period of at least
25 min before any additional treatments was given. Data
acquisition and analysis used a PowerLab System (ADIn-
struments, Australia). Left ventricular developed pressure
(LVDP) was calculated as the difference between left ven-
tricular systolic pressure (LVSP) and LVEDP, and work
index (RPP) as the product of LVDP and heart rate (HR).
Time derivatives of pressure were measured during con-
traction (+dP/dt) and relaxation (−dP/dt). The haemo-
dynamic parameters were computed using the software
Chart 5 (ADInstruments, Australia). Preischaemic values
of the parameters of haemodynamic function were mea-
sured at the end of the equilibration period prior to any
preischaemic intervention. Since the hearts in our exper-
iments contracted spontaneously, haemodynamic func-
tion is reflected in both LVDP and HR. For this reason,
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ing haemodynamic function. If RPP was less than
15,000 mmHg·beat/min at the end of the preischaemic
equilibration period, the heart was excluded from the
experiment.
Model of Surgically-Induced Heart Failure
Heart failure was surgically induced by ligation of the left
coronary artery as described previously [15] and modified
in our laboratory. In brief, 2 month old rats were anesthe-
tized with ketamine (75 mg/kg, i.p.) and medetomidine
(0.5 mg/kg, i.p.). Analgesia was induced by buprenorphine
(0.05 mg/kg, s.c.). The rats were intubated and ventilated
with a respirator for small animals (Harvard Apparatus).
Body temperature was maintained at 37°C during the sur-
gical procedure. An incision was made in the left side of
the chest to expose the fourth intercostal space. A 7–0
surgical suture was placed under the left coronary artery
and tied to complete occlusion of the artery. In sham-
operated animals (SO), the coronary artery was not li-
gated. The wound was closed with a 4–0 surgical suture.
Atipamezole (2.5 mg/kg, i.p.) was injected in order to fa-
cilitate recovery after the anaesthesia. After the surgery,
rats were placed into a recovery chamber (Vet Tech Solu-
tions Ltd) ventilated with oxygen. In coronary artery li-
gated (CAL) animals, approximately 92% survived and
were able to meet the inclusion criteria for the experi-
ments on isolated heart. All sham operated animals sur-
vived to 16 weeks after surgery. Animals were monitored
and cared for daily. Sixteen weeks after surgery, the ani-
mals were used for experiments on isolated heart as
shown in the Methods.
Experimental Groups
After a 25 min period of equilibration followed by pre-
ischaemic interventions, global normothermic ischaemia
(37°C) was induced for 30 min and then normothermic
perfusion was reinstated for 2 hr. Three series of experi-
ments were performed as detailed below and summarised
in Figures 1 and 2. In Series 1 and 2, experiments were
carried out on healthy male Wistar rats (250–275 g) whilst
in Series 3 rats with surgically-induced heart failure or
sham-operated rats were employed.
In Series 1 (Figure 1A), hearts were divided into a
Control group and 4 treatment groups (8–10 hearts/
group) according to the preischaemic protocol. Hearts of
the Control group were not subjected to any interven-
tion prior to ischaemia. Hearts of the three treatment
groups, after the equilibration period, were subjected to
the consecutive perfusion with Iso and Ade (3 min with
5 nM Iso and 5 min with 30 μM Ade) followed by a
washout period of different duration: 10 min (Iso/Ade-
10); 5 min (Iso/Ade-5) and zero min (Iso/Ade-0). Hearts
of the fourth treatment group ((Iso/Ade Mix)) were perfusedwith Ade for 1.5 min and then 3 min with the mixture of
Iso and Ade followed by another 1.5 min period of perfusion
with Ade (Figure 1A). Analysis of haemodynamic function
recovery, lactate dehydrogenase (LDH) release during reper-
fusion and infarct size, in this and the other series of experi-
ments, was performed in all hearts subjected to ischaemia.
Additional hearts (n = 9-10/group) of Control, Iso/Ade-10
and Iso/Ade-0 groups were freeze-clamped following
43 min preischaemia, ground under liquid nitrogen and
stored at −80°C for later analysis of PKC activity. Another
set of Control, Iso/Ade-0 and Iso/Ade Mix hearts (n = 7-8
in each group) were freeze-clamped at the end of the pre-
ishaemic protocol and used for the measurement of glyco-
gen content.
In Series 2 experiments, four groups (6–9 hearts/group)
were employed (Figure 1B). Two of the groups were Con-
trol and Iso/Ade with no washout period. In this series of
experiments and in the Series 3 experiments, Iso was used
at 10 nM. In preliminary experiments (data not shown),
we found that this concentration of Iso might give even
higher cardioprotective effect than 5 nM, which is import-
ant in terms of optimisation of the intervention, yet was
still in the range of normal pharmacological dose. Another
two groups of hearts were perfused with 0.2 μM CsA for
8 min prior to ischaemia with or without the Iso/Ade
treatment (Iso/Ade + CsA and CsA groups respectively).
Series 3 experiments were carried out on CAL and SO
rats. Hearts were divided into four groups (5–6 hearts/
group): Control and Iso/Ade groups of CAL and SO
rats. The experimental protocol of Control and Iso/Ade
groups (Figure 2) in this series of experiments was simi-
lar to those in Series 2 (Figure 1B). Infarct size was not
measured in these experiments because the CAL hearts
had already developed an infarct as a result of the left
descending coronary artery ligation.
Five additional CAL and 6 SO rats were used to confirm
the development of heart failure. Body weight and tibia
length were measured before the surgery and 16 weeks
after the operation. After 16 weeks post-operation, the rats
were killed by stunning and cervical dislocation, the hearts
and lungs excised and the wet weight of the hearts, left
ventricles and lungs were measured.
Assays
PKC activity
PKC activity was determined in freeze-clamped heart
powders using a kit supplied by Promega according to
the manufacturer’s instructions. The assay relies on a
change in charge of the fluorescent PepTag® C1 peptide
from +1 to −1 following phosphorylation. Bands were
visualized under UV light and the ratio of fluorescence
intensity of phosphorylated to non-phosphorylated pep-
tide was quantified using AlphaInotech ChemiImager
4400 with AlphaEase v5.5 software.












3 min perfusion with Iso at 5 nM
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Figure 1 Outline of the experimental protocols of series 1 and 2. Panel A – experimental protocol of the Series 1. Iso/Ade-0, Iso/Ade-5
and Iso/Ade-10 – consecutive perfusion with isoproterenol and adenosine with 0, 5, and 10 min washout period respectively; Iso/Ade Mix –
perfusion with the mixture of isoproterenol and adenosine. Panel B – experimental protocol of the Series 2. Control; Iso/Ade – consecutive isoproterenol/
adenosine treatment with no washout period (similar to that of Iso/Ade-0 in the Series 1); CsA – perfusion with cyclosporine A; and Iso/Ade +CsA –
consecutive isoproterenol/adenosine treatment combined with perfusion with Cyclosporine A.
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Glycogen content was assessed by measuring the glucose
released from glycogen breakdown by amyloglucosidase
based on the method described by Passonneau [16] and
expressed as μmol glucose per gram tissue. A sample
(70 mg) of the frozen tissue was suspended in 1 ml of
0.3 M perchloric acid (4°C), homogenized with a Poly-
tron and 50 μl of the suspension were incubated with
0.5 ml of 50 mM Na Acetate Buffer (pH 5.5) containing0.02% BSA and 50 μg/ml amyloglucosidase (Sigma) at
room temperature for 2 hr. The samples were then
centrifuged at 10000 g for 10 min and glucose content
was assessed using a Glucose (HK) Assay Kit (Sigma)
according to the manufacturer’s instruction. Briefly,
0.4 ml of the supernatant was mixed with 1 ml of the
glucose assay reagent. Glucose content was measured
spectrophotometrically (340 nm) after incubation at room









5 min perfusion with 30 µM Ade Global Normothermic Ischaemia 








Figure 2 Outline of the experimental protocol of series 3.
Panel A – model of surgically-induced heart failure. CAL – left
anterior descending coronary artery ligation; SO – sham-operated
heart. Panel B – experimental protocol of series 3. The CAL and SO
hearts were divided to two groups each: Control CAL, Iso/Ade CAL,
Control SO and Iso/Ade SO. The Iso/Ade protocol was similar to those
of Iso/Ade-0 group in the Series 1 (Figure 1A) and Iso/Ade group in
Series 2 (Figure 1B).
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down was determined by subtracting glucose in samples
incubated without amyloglucosidase from those incubated
with the enzyme.
LDH activity
LDH activity was determined in the effluent perfusate
collected from the hearts of all groups prior to ischemia
and during each 5 min over the first 30 min of reperfu-
sion as described earlier [17] and modified at our lab:
80 μl of the sample was added to 910 μl of the buffer
(pH 7.4) containing 100 mM triethanolamine and 100 μM
reduced β-nicotinamide adenine dinucleotide (NADH).
After addition of 10 μl of 0.1 M sodium pyruvate to the re-
action mixture, the change of absorbance at 340 nm (A340)
was recorded using a spectrophotometer over 10 min at
37°C. LDH activity was calculated according to the rate of
A340 decrease.
Infarct Size
Infarct size was determined as described previously [18].
Hearts were stained with 1% of triphenyltetrazoliumchloride after 2 h of reperfusion, frozen at -20°C and sliced
into 6 slices. Necrotic and intact areas of each side for each
of heart slices were determined using AlphaEase v5.5 soft-
ware and the total necrotic and intact area of ventricular
myocardium of each heart was calculated. Since the entire
heart was at risk from global ischemia, the infarct size was
expressed dividing the sum of necrotic areas by the sum of
total slice areas of the 6 slices to obtain the percentage of
necrosis.
Statistical Analysis
Data are presented as mean ± SEM. Statistical signifi-
cances of the differences between groups were evaluated
by one-way ANOVA followed by Tukey's multiple com-
parison post hoc test or two-tailed unpaired Student’s t-
test (morphometric measurements of CAL and SO rats
in the Series 3 experiments) using the software Graph-
Pad Prism, Version 4.03. Differences were considered
significant where P < 0.05.
Results
Optimization of the protocol of Iso/Ade treatment with a
clinically relevant dose of Isoproterenol
In the Iso/Ade group, RPP during heart perfusion with 5
nM Iso reached a maximum of 259.4 ± 12.4% of the pre-
treatment value, mostly due to an increase in LVDP.
RPP measured at the end of perfusion with 30 μM Ade
fell to 42.3 ± 7.0% of the pre-treatment value, due to a
significant reduction of both HR and LVDP. In Table 1,
we show that during reperfusion, recovery of RPP in the
Control group was 28%. However, perfusion with low
Iso concentration (5 nM) followed by 30 μM Ade imme-
diately prior to rendering the heart ischaemia (Iso/Ade-0
group), improved recovery in RPP to 76%. Similar recov-
ery was achieved when the duration of perfusion prior
to commencing ischaemia was extended to 5 or 10 min
(Iso/Ade-5 and Iso/Ade-10 groups).
The improved RPP recovery during reperfusion was ac-
companied by considerably reduced LVEDP and reflected
improved recovery of LVDP with no significant change in
HR. The time derivative during contraction was signifi-
cantly higher in all three Iso/Ade groups than in Control
group, whereas recovery of -dP/dt was significantly im-
proved only in hearts of the Iso/Ade-0 group. The param-
eters of haemodynamic function recovery did not differ
significantly between the three Iso/Ade groups but were
the highest in Iso/Ade-0 group. Protection against nec-
rotic damage showed a similar pattern to the recovery of
haemodynamic function. Thus, LDH release during the
first 30 min of reperfusion (Figure 3A) and infarct size at
the end of reperfusion (Figure 3B) were significantly lower
in Iso/Ade groups compared to Control. However infarct
size in the group Iso/Ade-0 was notably lower compared
to both Control and Iso/Ade-5 groups.




Reperfusion (Percentage preischaemic value)
Control (n = 7) Iso/Ade-0 (n = 10) Iso/Ade-5 (n = 9) Iso/Ade-10 (n = 8)
LVDP (mmHg) 75.1 ± 2.5
% of initial values
29.4 ± 5.7 88.9 ± 7.2 *** 73.6 ± 8.3 * 78.3 ± 14.9 *
HR (beat/min) 277.6 ± 4.2 102.5 ± 11.4 86.9 ± 5.6 94.5 ± 3.2 71.6 ± 8.9
RPP (mmHg · beat/min) 20802 ± 713 28.5 ± 5.2 76.3 ± 6.9 *** 68.5 ± 7.0 ** 73.3 ± 10.5 **
+dP/dt (mmHg/s) 3082 ± 117 30.2 ± 2.5 65.2 ± 6.9 ** 58.6 ± 5.3 * 60.4 ± 8.5 *
-dP/dt (mmHg/s) −2027 ± 83 42.7 ± 4.4 85.5 ± 7.2 ** 65.6 ± 8.2 71.5 ± 8.9
Maximal LVEDP at Reperfusion (mmHg) - 98.7 ± 7.5 50.0 ± 4.4 *** 62.1 ± 8.2 ** 63.2 ± 6.5 **
Haemodynamic function was determined at the end of the equilibration period prior to ischaemia and after 60 min reperfusion.
* P < 0.05, ** P < 0.01, *** P < 0.001 vs. Control.
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of the pre-ischaemic protocol, was 1.5 fold higher com-
pared to both Control and Iso/Ade-10 groups (Figure 4).
Glycogen content was halved in hearts treated con-
secutively with Iso and Ade, but simultaneous perfusion
of hearts with these drugs had no significant effect on
this parameter (Figure 5).Effect of the combined treatment with Iso, Ade and
cyclosporine A on ischaemia/reperfusion injury
In the Iso/Ade group of the second series of experiments,
RPP during heart perfusion with 10 nM of Iso reached a
maximum of 346.1 ± 26.9% of the pre-treatment value,
significantly exceeding RPP increase in Series 1 hearts
treated with 5 nM Iso (P < 0.05). This elevation of RPP
was mostly due to increase in LVDP. RPP measured at the
end of perfusion with 30 μM Ade fell to 36.8 ± 7.6% of the
pre-treatment value due to a significant reduction of both
HR and LVDP. The MPTP inhibitor CsA significantly in-
creased RPP recovery compared to Control (Table 2) and
was as effective as the consecutive Iso/Ade treatment in
terms of reduction of infarct size (Figure 6B). LDH activity
in the effluent perfusate during reperfusion was also sig-
nificantly reduced in these hearts (Figure 6A). However
perfusion of hearts with CsA together with the consecu-
tive Iso/Ade treatment (Iso/Ade + CsA group), at clinically
relevant concentration of these drugs, did not bring about
any additive protective effect; infarct size and LDH release
were similar to those of Iso/Ade group.Consecutive Iso/Ade treatment protects hearts with
surgically-induced heart failure
At the time of the ligation of left coronary artery, no sig-
nificant difference in body weight or tibia length was de-
tected between sham-operated (SO) and Coronary Artery
Ligation (CAL) animals. After 16 weeks post-surgery, there
was no difference in body weight between the two groups.
However, significant increases in heart and lung weights,
heart and lung to body weight ratios, as well as tibia length
to body weight ratio in the CAL animals were observed(Table 3) indicating both cardiac hypertrophy and cardiac
insufficiency.
During heart perfusion with 10 nM of Iso, RPP reached
a maximum of 401.3 ± 30.8% of the pre-treatment value in
SO group and 343.3 ± 52.4% in CAL group, mostly due to
increase in LVDP. This parameter in the SO group, but
not in the CAL group, was significantly higher than in
Series 1 where the hearts were treated with 5 nM Iso
(P < 0.01). RPP measured at the end of perfusion with
30 μM Ade fell to 43.5 ± 8.0% of the pre-treatment
value in SO hearts and to 56.6 ± 9.3% in CAL hearts,
due to a significant reduction of HR and return of
LVDP to the pre-treatment value. There was no signifi-
cant difference in changes of RPP in response to the
perfusion with Ade between SO and CAL groups. Haemo-
dynamic function recovery of both SO and CAL groups of
hearts following ex-vivo ischaemia/reperfusion was very
poor and did not significantly differ from each other
(Table 4). Thus, LVDP and RPP reached only 20–25% of
the initial preischaemic values. Iso/Ade treatment signifi-
cantly improved haemodynamic function recovery of both
SO and CAL hearts with RPP reaching 70% of the pre-
ischaemic value. LDH activity during reperfusion was
highest in Control CAL hearts and was significantly
higher not only than Iso/Ade treated hearts of SO and
CAL groups but also than Control SO hearts (Figure 7).
Thus, necrotic damage was greatest in the untreated
failing hearts but Iso/Ade treatment was able to protect
the failing hearts at least as effectively as the sham-
operated ones.
Discussion
Optimisation of the Iso/Ade treatment and its
translational significance
Our results show that Iso at its low dose (5–10 nM),
followed by the perfusion with 30 μM Ade, can success-
fully protect hearts against ischaemia/reperfusion injury.
In fact, when Iso was perfused at 10 nM, the protective
effect was similar to the higher concentration of Iso (200
nM) used in our previous experiments [4]. Since both
Iso and Ade are used in clinical settings and can protect
AB
Figure 3 Lactate dehydrogenase (LDH) activity and infarct size in hearts of the Series 1. The experiments were carried out on Control
(n = 7) and Iso/Ade groups with 0 (n = 9), 5 (n = 9), and 10 (n = 9) min washout periods. Panel A - LDH activity in the effluent perfusate during
30 min reperfusion. Differences between Control and all three Iso/Ade groups (measured for the corresponding data points) were statistically
significant (P < 0.05) at all data points. There was no significant difference in LDH activity between the Iso/Ade groups. Panel B – Infarct
size. Mean ± SEM (columns) and representative images of the corresponding heart slices stained with 2,3,5-triphenyltetrazolium chloride
(TTC). ** P < 0.01, *** P < 0.001 vs. Control; # P < 0.05 vs. Iso/Ade group with zero min washout period.
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Ade treatment has strong potential for translation into
clinical practice. Furthermore, the use of these drugs at
low doses will minimise other drug interactions. Thiswork also demonstrates that there is a window of at least
10 min within which the index ischaemia can be started
and strong cardioprotection still be observed. However,
it is clear that, the shorter the period between the end of
AB
Figure 4 Protein Kinase C (PKC) activity in hearts of Experimental Series 1. PKC activity was measured using non-radioactive PepTag® assay
and is expressed as Mean ± SEM of a ratio of fluorescence intensity of phosphorylated and non-phosphorylated PepTag® C1 peptide (Panel B)
which is proportional to the PKC activity. PKC activity was measured in Control (C, n = 10), Iso/Ade-0 (n = 9) and Iso/Ade-10 (n = 9) groups.
Panel A – Representative image of the phosphorylated and non-phosphorylated PepTag® C1 peptide under UV light. ** P < 0.01 vs. Control.
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cardioprotective efficacy of the treatment will be. Thus
in our experiments, infarct size in hearts with no wash-
out period (Iso/Ade-0 group) was significantly smaller
than in both Control and Iso/Ade-5 hearts. Furthermore,
only in Iso/Ade-0 hearts was -dP/dt recovery significantly
higher than in controls. This might be explained by the
index ischaemia in these hearts commencing while PKC
remained activated, potentially leading to more effective
survival signalling.
Having established that clinically-relevant doses of iso-
proteronol and adenosine are cardioprotective and was
optimal when applied immediately prior to ischaemia,
the next step was to identify the target of this powerful
cardioprotective intervention. Our earlier work suggested
that reduced ROS production and consequent inhibitionof MPTP opening were likely targets [4]. If this is the case,
protection should not be further enhanced by direct inhib-
ition of the MPTP by Cyclosporin A and we confirmed
this to be the case.
Role of MPTP and Cardiac Glycogen in cardioprotection
by Iso/Ade treatment
We [9] and others [19-21] have shown that MPTP open-
ing is a key factor of irreversible damage during reperfu-
sion and that its prevention underlies cardioprotection by
a variety of preconditioning [12] and post-conditioning
protocols [10]. Thus, it was hypothesized that the protec-
tion associated with ischaemic preconditioning could be
attributed to a decreased probability of MPTP opening
[9,22]. Ovize et al. proposed MPTP inhibition as the




























Control Iso/Ade Iso/Ade Mix
*
Figure 5 Glycogen content in hearts of Experimental Series 1. Glycogen content in myocardium of Control hearts (n = 8), hearts treated
consecutively with Iso and Ade (Iso/Ade group, n = 8) and hearts treated with the mixture of Iso and Ade (Iso/Ade Mix, n=7) was measured prior
to ischaemia. * P < 0.05 vs. control.
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preconditioning [11] and a variety of pharmacologically-
induced cardioprotective interventions [12] also rely on
the MPTP inhibition. In our recent study with Iso/Ade
treatment, where Iso was used at relatively high concen-
tration (200 nM), the treatment resulted in a dramatic
reduction of calcium-induced mitochondria swelling
implicating MPTP inhibition as an end effector of the
cardioprotective mechanism [4].
In the present work, we used the MPTP inhibitor CsA
in order to confirm a role for MPTP inhibition in the
cardioprotection afforded by Iso/Ade treatment. We found
that CsA improved RPP recovery and significantly reduced
necrotic damage to myocardium during reperfusion. These
results are consistent with earlier data shown by us [23,24]
and others [25-27] confirming a cardioprotective effect of
CsA. However, no additive cardioprotective effect was seen
when consecutive treatment with 10 nM isoproterenol and





LVDP (mmHg) 75.8 ± 2.9
% of initial values
HR (beat/min) 288.3 ± 3.9
RPP (mmHg · beat/min) 21854 ± 889
+dP/dt (mmHg/s) 2969 ± 94
-dP/dt (mmHg/s) −2074 ± 84
Maximal LVEDP at Reperfusion (mmHg) - 98.6 ± 5
Haemodynamic function was determined at the end of equilibration period prior to
group in this series of experiments was similar to that of Iso/Ade-0 group in Experim
* P < 0.05, ** P < 0.01, *** P < 0.001 vs. Control.These data suggest that cardioprotection by the Iso/Ade
treatment is mediated through inhibition of the MPTP.
It has been reported that protection via ischaemic pre-
conditioning is associated with glycogen depletion lead-
ing to less anaerobic glycolysis during the subsequent
prolonged ischaemia, and hence reduced accumulation
of lactate and H+. This causes a smaller decrease in
intracellular pH during ischaemia and thus less compen-
satory increases in intracellular Na+ and Ca2+ [28]. The
decreased Ca2+ loading will reduce the likelihood that
the MPTP opens which might partially explain the ob-
served cardioprotection [29]. Glycogen breakdown has
also been linked to attenuation of the loss of hexokinase
2 (HK-2) binding to mitochondria that occurs during
ischaemia [30]. The binding of HK-2 plays an anti-
apoptotic role and inhibits MPTP opening [31,32] and
there is an inverse correlation between the extent of
HK-2 binding at the end of ischaemia and infarct size
[30]. Increase HK-2 binding at the end of ischaemiaAde groups with or without cyclosporine A
Reperfusion (Percentage preischaemic value)
= 7) Iso/Ade (n = 6) CsA (n = 5) Iso/Ade + CsA (n = 6)
39.0 ± 6.6 100.5 ± 14.2 * 89.5 ± 14.4 97.8 ± 16.9 *
96.0 ± 3.5 93.1 ± 3.1 99.3 ± 4.7 102.9 ± 2.9
38.8 ± 7.5 93.0 ± 12.0 ** 86.3 ± 13.3 * 100.3 ± 11.2 **
34.2 ± 4.6 81.3 ± 12.3 * 66.4 ± 13.3 87.2 ± 14.3 *
42.7 ± 4.7 93.6 ± 12.4 ** 71.7 ± 8.3 90.8 ± 13.5 *
.6 53.9 ± 13.2 ** 78.2 ± 8.6 65.9 ± 4.2 *
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*** **
**
Figure 6 LDH activity and infarct size in hearts in Experimental Series 2. The experiments were carried out on Control (n = 9), Iso/Ade (n = 9),
cyclosporine A (CsA, n = 6) and Iso/Ade + CsA (n = 8) groups of hearts. The perfusion protocol of Iso/Ade group in this series of experiments was
similar to that of Iso/Ade-0 group in Experimental Series 1. Panel A – LDH activity in the effluent perfusate during 30 min reperfusion. Differences
between control and three other groups (measured for the corresponding data points) were statistically significant (P < 0.05) at all data points.
There was no significant difference in LDH activity between the three intervention groups. Panel B – Infarct size. Mean ± SEM (columns) and
representative images of the corresponding heart slices stained with TTC. ** P < 0.01, *** P < 0.001 vs. Control.
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glycogen content prior to ischaemia. This leads to a reduc-
tion in tissue glucose-6-phosphate levels and acidification
during ischaemia, which mediate HK-2 dissociation from
mitochondria [30]. The data of Figure 5 confirm that the
consecutive Iso/Ade treatment also depleted glycogenTable 3 Effects of the left coronary artery ligation (CAL) on ca
Procedure BW (g) HW (g) LW (g) Tibia (mm) HW/B
Sham (n = 6) 502.2 ± 8.0 1.56 ± 0.04 1.62 ± 0.04 46.7 ± 0.5 3
CAL (n = 5) 491.4 ± 25.6 2.42 ± 0.20 ** 1.97 ± 0.13 * 46.1 ± 0.6 4.9
BW – body weight; HW – heart weight; LW – lung weight. * P < 0.05, ** P < 0.01, ***content considerably consistent with this mechanism,
whereas the reduction in glycogen content following
simultaneous application of the drugs was not signifi-
cant and was accompanied by considerably less cardio-
protection. However, reduced glycogen content cannot
entirely account for the cardioprotection since we haverdiac morphology
W (mg/g) LW/BW (mg/g) HW/Tibia (mg/mm) LW/Tibia (mg/mm)
.1 ± 0.1 3.2 ± 0.1 3.3 ± 0.1 3.5 ± 0.1
± 0.4 *** 4.0 ± 0.1 *** 5.3 ± 0.4 *** 4.3 ± 0.2 **
P < 0.001 vs. Sham.
Table 4 Haemodynamic function in coronary artery ligation (CAL) and sham-operated (SO) Iso/Ade groups of hearts
Parameters Pre-Ischaemia
(n = 20)
Reperfusion (Percentage preischaemic value)
Control SO (n = 5) Iso/Ade SO (n = 5) Control CAL (n = 5) Iso/Ade CAL (n = 5)
LVDP (mmHg) 75.2 ± 4.3
% of initial values
24.1 ± 3.9 65.4 ± 9.1 * 20.7 ± 4.0 69.6 ± 15.2 **
HR (beat/min) 271.1 ± 7.8 89.1 ± 19.4 107.5 ± 7.6 94.4 ± 3.0 99.0 ± 4.5
RPP (mmHg · beat/min) 20454 ± 1333 22.5 ± 5.9 66.3 ± 9.8 * 19.7 ± 4.0 69.0 ± 16.3 *
+dP/dt (mmHg/s) 2596 ± 154 31.7 ± 3.3 82.4 ± 20.8 66.3 ± 15.8 87.2 ± 14.3
-dP/dt (mmHg/s) −1868 ± 138 37.8 ± 2.7 86.5 ± 22.1 ** 40.4 ± 4.5 77.0 ± 14.3
Maximal LVEDP at
Reperfusion (mmHg)
- 91.9 ± 19.1 28.7 ± 12.2 * 67.3 ± 9.9 20.2 ± 21.1
Haemodynamic function was determined at the end of equilibration period prior to ischaemia and after 60 min reperfusion. The perfusion protocol of Iso/Ade
groups in this series of experiments was similar to that of Iso/Ade-0 group in Experimental Series 1.
* P < 0.05, ** P < 0.01 vs. a corresponding Control.
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be induced by high dose of isoproterenol alone, yet this
treatment was less cardioprotective than the consecutive
treatment with isoproterenol and adenosine [4]. Thus ad-
enosine may contribute to cardioprotection through
glycogen independent mechanisms that improve haemo-
dynamic function recovery during reperfusion and inhibit
MPTP opening [4].
Consecutive Iso/Ade treatment protects hearts with
surgically-induced heart failure
Since the majority of patients undergoing cardiac sur-
gery suffer from co-morbid illnesses, for clinical use of
consecutive Iso/Ade treatment it is necessary to confirm
its efficacy in an experimental model of the diseased
heart [33,34]. In general, the presence of co-morbid ill-
ness renders the myocardium resistant to cardioprotec-
tion against infarction by physical or pharmacological
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Figure 7 LDH activity in hearts of Experimental Series 3. LDH
activity was measured in the effluent perfusate during 30 min
reperfusion. The perfusion protocol of Iso/Ade groups in this series
of experiments was similar to that of Iso/Ade-0 group in the
Experimental Series 1. LDH activity is presented for Control and Iso/Ade
groups in sham-operated hearts (SO, n = 6 in each group) and failing
hearts after the left descending coronary artery ligation (CAL, n = 5 in
control and n = 6 in Iso/Ade group). * P < 0.05 vs. corresponding
Control (either SO or CAL); # P < 0.05 vs. Control CAL.ventricular hypertrophy does not compromise the effi-
cacy of cardioprotective interventions such as ischaemic
preconditioning but heart failure abolishes any beneficial
effect [33,35,36]. Heart failure is a complex clinical syn-
drome, the etiology of which generally stems from pre-
existing ischaemic heart/coronary artery disease, or it is
of non-ischaemic and/or idiopathic origin [37,38]. It is
characterized by the progressive inability of the heart to
fill with, and eject adequate amounts of blood to meet
the needs of the body [39].
Ligation of the left descending coronary artery in our
experiments rendered a significant increase in heart and
lung weight to body weight and tibia length ratios (Table 3)
in 16 weeks after the surgery indicating both cardiac
hypertrophy and cardiac insufficiency.
Consistent with the dose-dependent effect, preischae-
mic perfusion of SO hearts with 10 nM Iso resulted in a
significantly higher increase of RPP than in hearts of
Series 1 treated with 5 nM Iso. In the CAL group, RPP
was also increased considerably during perfusion with
10 nM Iso but this was not significantly higher than in
hearts treated with 5nM Iso. Thus, although the myocar-
dium of rats with surgically-induced heart failure model
showed somewhat reduced β-adrenergic reactivity, they
still responded well to the β-adrenergic stimulation.
Control CAL hearts suffered more severe necrotic damage
during reperfusion than their sham-operated counterparts
as reflected in the released LDH activity during reperfu-
sion which was twice as high in these hearts as compared
to the non-treated SO hearts (Figure 7). Nevertheless, the
haemodynamic function recovery in Iso/Ade treated CAL
hearts was similar to SO hearts whilst LDH release was
suppressed more strongly than in the sham-operated
hearts. This implies that heart failure in our experiments
did not compromise the cardioprotective effect of con-
secutive Iso/Ade treatment and that the survival signal
transduction pathways activated by this treatment were
still responsive in spite of the developed heart failure.
The results of our study may represent a significant step
towards translation of the consecutive Iso/Ade treatment
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and cardiopulmonary bypass.
Conclusions
The novel findings of our study are as follows:
1. Strong cardioprotective effect of PKA/PKC
activation can be achieved by heart perfusion with
Iso at the clinically relevant concentration of 5–10
nM followed by perfusion with Ade.
2. The cardioprotective efficacy of PKA/PKC activation
remains for at least 10 min after the intervention.
From a practical point of view, this means that this
protective intervention will still be effective even if it
is performed some time before the ischaemic
incident (i.e. cardiac surgery with cardioplegic
arrest).
3. In contrast to a number of studies showing loss or
attenuation of cardioprotection in diseased or ageing
hearts, consecutive Iso/Ado treatment can protect
the failing heart effectively. This efficacy of the
treatment in a relevant comorbidity model increases
the likelihood of successful translation into clinical
practice.
4. Our data suggest a key role of MPTP inhibition in
the cardioprotective effect of this treatment.
Glycogen depletion of the myocardium induced by
the treatment prior to ischaemia is implicated in the
mechanism underlying MPTP inhibition and
cardioprotection.
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